<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01916486</url>
  </required_header>
  <id_info>
    <org_study_id>H13-00715</org_study_id>
    <nct_id>NCT01916486</nct_id>
  </id_info>
  <brief_title>Vitality: Promoting Cognitive Function in Older Adults With Chronic Stroke</brief_title>
  <acronym>Vitality</acronym>
  <official_title>Complex Mental and Social Activities to Promote Cognitive Function in Older Adults With Chronic Stroke: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will conduct a randomized controlled trial study to provide preliminary
      evidence of efficacy of exercise training or a complex mental and social activities program
      for improving cognitive function in older adults with chronic stroke, compared with a stretch
      and relaxation program.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 119 adults diagnosed with chronic stroke will be randomized to either a 6-month
      twice-weekly exercise program, complex mental and social activities program, or stretch and
      relaxation program. After 6 months of intervention, they will be followed for an additional 6
      months. There will be four measurement sessions: baseline, 3 months, 6 months (end of
      intervention period); and 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in cognitive function as measured by the Alzheimer's Disease Assessment Scale Cognitive Subscale Plus (ADAS-Plus) at 6 months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>ADAS-Cog 13 + additional measures of executive functions. For ADAS-Cog 13, higher scores indicate greater impairment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in executive functions as measured by the Stroop Test.</measure>
    <time_frame>Baseline, 3 months (for subset of cognitive outcomes), 6 months, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in executive functions as measured by the Tower of London Test.</measure>
    <time_frame>Baseline, 3 months (for subset of cognitive outcomes), 6 months, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in processing speed and executive functions as measured by the Trail Making Tests (Parts A &amp; B).</measure>
    <time_frame>Baseline, 3 months (for subset of cognitive outcomes), 6 months, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in category fluency.</measure>
    <time_frame>Baseline, 3 months (for subset of cognitive outcomes), 6 months, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in memory and executive functions as measured by the verbal digits forward and backward tests.</measure>
    <time_frame>Baseline, 3 months (for subset of cognitive outcomes), 6 months, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in instrumental activities of daily living as measured by the Instrumental Activities of Daily Living Scale.</measure>
    <time_frame>Baseline, 3 months, 6 months, and 12 months</time_frame>
    <description>Higher scores indicate better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fatigue as measured by the Fatigue Severity Scale.</measure>
    <time_frame>Baseline, 3 months, 6 months, and 12 months</time_frame>
    <description>Higher scores indicate greater fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in physical activity level as measured by the Community Healthy Activities Model Program for Seniors Questionnaire (CHAMPS).</measure>
    <time_frame>Baseline, 3 months, 6 months, and 12 months</time_frame>
    <description>Acquired on a monthly basis. Higher scores indicate greater activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in community mobility as measured by the Life-space Assessment (LSA).</measure>
    <time_frame>Baseline, 3 months, 6 months, and 12 months</time_frame>
    <description>Higher scores indicate greater community mobility.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in leisure activity as measured by the Shortened Nottingham Leisure Scale.</measure>
    <time_frame>Baseline, 3 months, 6 months, and 12 months</time_frame>
    <description>Acquired on a monthly basis. Higher scores indicate greater leisure activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in general balance and mobility as measured by the Short Physical Performance Battery.</measure>
    <time_frame>Baseline, 3 months, 6 months, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in functional capacity as measured by the 6 Minute Walk Test.</measure>
    <time_frame>Baseline, 3 months, 6 months, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in general balance and mobility as measured the Timed Up-and-Go Test.</measure>
    <time_frame>Baseline, 3 months, 6 months, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quadriceps strength.</measure>
    <time_frame>Baseline, 3 months, 6 months, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in grip strength.</measure>
    <time_frame>Baseline, 3 months, 6 months, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mood as measured by the Center for Epidemiologic Studies Depression Scale.</measure>
    <time_frame>Baseline, 3 months, 6 months, and 12 months</time_frame>
    <description>Higher scores indicate greater impairment in mood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quality of life as measured by the European Quality of Life-5 Dimensions (EQ-5D).</measure>
    <time_frame>Baseline, 3 months, 6 months, and 12 months</time_frame>
    <description>Acquired on a monthly basis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quality of life as measured by European Quality of Life-5 Dimensions Visual Analog Scale (EQ-5D VAS).</measure>
    <time_frame>Baseline, 3 months, 6 months, and 12 months</time_frame>
    <description>Acquired on a monthly basis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Cognitive Function as Measured by the Alzheimer's Disease Assessment Scale Cognitive Subscale Plus (ADAS-Cog Plus) at 12 months</measure>
    <time_frame>Baseline, 3 months, 6 months, and 12 months</time_frame>
    <description>ADAS-Cog 13 + additional measures of executive functions. For ADAS-Cog Plus, higher scores indicate greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in sleep quality as measured by the Pittsburgh Sleep Index.</measure>
    <time_frame>Baseline, 3 months, 6 months, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in sleep quality as measured by the Motion Watch 8.</measure>
    <time_frame>Baseline, 3 months, 6 months, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in lipid profile.</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in insulin sensitivity.</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care resource usage.</measure>
    <time_frame>Baseline, 3, and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Stroke</condition>
  <condition>Chronic Stroke</condition>
  <arm_group>
    <arm_group_label>Exercise training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice-weekly for the 6-month duration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Complex mental and social activities</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice-weekly for the 6-month duration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control: stretching and relaxation program</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Twice-weekly for the 6-month duration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise training</intervention_name>
    <description>The EX Program will provide objective progression in the guided exercises of each participant.</description>
    <arm_group_label>Exercise training</arm_group_label>
    <other_name>EX Program</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Complex mental and social activities</intervention_name>
    <description>The Cog-Plus Program will engage participants in activities promoting cognitive function and socialization.</description>
    <arm_group_label>Complex mental and social activities</arm_group_label>
    <other_name>Cog-Plus Program</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Control: stretching and relaxation program</intervention_name>
    <description>The CON Program consist of stretches, deep breathing and relaxation techniques, general posture education, and general core control exercises in the sitting position.</description>
    <arm_group_label>Control: stretching and relaxation program</arm_group_label>
    <other_name>CON Program</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The study will specifically recruit individuals who had an ischemic or hemorrhagic stroke
        and have probable mild cognitive impairment.

        In addition, individuals must meet the following inclusion criteria:

          1. Aged 55 years or over;

          2. Have a history of a single stroke of at least one year prior to study enrolment;

          3. Mini-Mental State Examination (MMSE) (5) score of â‰¥ 20 at screening, including a
             perfect score on the 3-step command to ensure intact comprehension and ability to
             follow instructions;

          4. Have subjective cognitive complaints;

          5. Community-dwelling;

          6. Lives in Metro Vancouver;

          7. Able to comply with scheduled visits, treatment plan, and other trial procedures;

          8. Must be able to read, write, and speak English in which psychometric tests are
             provided with acceptable visual and auditory acuity;

          9. Stable on a fixed dose of cognitive medications (e.g., donepezil, galantamine,
             rivastigmine, memantine, etc.) that is not expected to change during the 12-month
             study period, or, if they are not on any of these medications, they are not expected
             to start them during the 12-month study period;

         10. Able to walk for a minimum of six metres with rest intervals with or without assistive
             devices;

         11. Have an activity tolerance of 60 minutes with rest intervals;

         12. Not currently participating in any regular therapy or progressive exercise; and

         13. Provide a personally signed and dated informed consent document indicating that the
             individual (or a legally acceptable representative) has been informed of all pertinent
             aspects of the trial. In addition, an assent form will be provided at baseline and
             again at regular intervals.

        Exclusion Criteria:

          1. Diagnosed with dementia of any type;

          2. Diagnosed with another type of neurodegenerative or neurological condition (ie.
             Parkinson's disease) that affects cognitive function and mobility;

          3. At high risk for cardiac complications during exercise and/or unable to self-regulate
             activity or to understand recommended activity level (i.e., Class C of the American
             Heart Risk Stratification Criteria);

          4. Have clinically significant peripheral neuropathy or severe musculoskeletal or joint
             disease that impairs mobility, as determined by his/her family physician;

          5. Taking medications that may negatively affect cognitive function, such as
             anticholinergics, including agents with pronounced anticholinergic properties (e.g.,
             amitriptyline), major tranquilizers (typical and atypical antipsychotics), and
             anticonvulsants (e.g., gabapentin, valproic acid, etc.); or

          6. Have aphasia as judged by an inability to communicate by phone.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janice J Eng, PhD, PT</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teresa Liu-Ambrose, PhD, PT</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Hall, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Waterloo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charlie Goldsmith, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simon Fraser University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer Davis, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura Middleton, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Waterloo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ging-Yuek Robin Hsiung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>July 23, 2013</study_first_submitted>
  <study_first_submitted_qc>August 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2013</study_first_posted>
  <last_update_submitted>June 17, 2019</last_update_submitted>
  <last_update_submitted_qc>June 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Teresa Liu-Ambrose</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

